Edge Capital Group’s Royalty Pharma RPRX Stock Holding History

Edge Capital Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-58,936	Closed	-$2.12M	–	382
2023 Q1	$2.12M	Buy	58,936 +39,117	+197%	+$1.45M	0.13%	121
2022 Q4	$783K	Buy	19,819 +2,721	+16%	+$114K	0.05%	157
2022 Q3	$687K	Buy	+17,098	New	+$730K	0.06%	162

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Edge Capital Group's RPRX Position: Q2 2023 in Review

Edge Capital Group sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 58,936 shares — an estimated $2.12M sold.

Edge Capital Group first reported a position in RPRX in Q3 2022 and held it in 3 quarters. The position peaked at $2.12M in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Edge Capital Group reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Edge Capital Group sold 58,936 Royalty Pharma shares in Q2 2023, an estimated $2.12M.
Edge Capital Group first reported a position in Royalty Pharma in Q3 2022 and held it in 3 quarters.
Edge Capital Group's Royalty Pharma position peaked at $2.12M in Q1 2023.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Edge Capital Group's 13F filing for Q2 2023, filed 8 Aug 2023.